Sequoia Financial Advisors LLC Acquires 518 Shares of Zoetis Inc. $ZTS

Sequoia Financial Advisors LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 1.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,283 shares of the company’s stock after acquiring an additional 518 shares during the period. Sequoia Financial Advisors LLC’s holdings in Zoetis were worth $6,126,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ZTS. Lindbrook Capital LLC increased its stake in shares of Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock valued at $612,000 after purchasing an additional 65 shares during the last quarter. Scott & Selber Inc. increased its holdings in Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after purchasing an additional 67 shares in the last quarter. Secure Asset Management LLC lifted its stake in Zoetis by 2.9% during the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after acquiring an additional 68 shares in the last quarter. Quotient Wealth Partners LLC boosted its stake in shares of Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock worth $521,000 after buying an additional 72 shares during the last quarter. Finally, Menard Financial Group LLC grew its position in Zoetis by 3.8% during the first quarter. Menard Financial Group LLC now owns 2,032 shares of the company’s stock valued at $305,000 after buying an additional 75 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.8%

Zoetis stock opened at $142.29 on Tuesday. The business has a fifty day moving average of $149.04 and a two-hundred day moving average of $154.19. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a market cap of $63.06 billion, a P/E ratio of 24.49, a P/E/G ratio of 2.26 and a beta of 0.90. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s payout ratio is currently 34.42%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ZTS. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Argus reissued a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.